Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESET C2 neoadjuvant pembrolizumab and organ-sparing strategy in localized dMMR colon cancer
2026-525214-62-00Phase 2Authorised
- Sponsor
- Region Zealand
- Start
- May 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in colon adenocarcinoma and Microsatellite Instability-High/Mismatch Repair Deficient Colorectal Cancer (MSI-H/dMMR) (3 arms), sponsored by Region Zealand. Primary endpoint: Complete clinical response. Planned start May 2026; status: authorised.
02
Drugs
03
Conditions
colon adenocarcinomaMicrosatellite Instability-High/Mismatch Repair Deficient Colorectal Cancer (MSI-H/dMMR)
Beyond the preview
Go deeper on 2026-525214-62-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525214-62-00.